| Literature DB >> 33790496 |
Danica Francisco1, Elizabeth Paz-Pacheco1, Perie Adorable-Wagan1.
Abstract
BACKGROUND: Philippine studies on primary hyperparathyroidism (PHPT) and preoperative localization are scarce, making improvements on detection and recognition particularly difficult.Entities:
Keywords: parathyroid localization; parathyroidectomy; primary hyperparathyroidism
Year: 2020 PMID: 33790496 PMCID: PMC7992305 DOI: 10.15605/jafes.035.01.13
Source DB: PubMed Journal: J ASEAN Fed Endocr Soc ISSN: 0857-1074
Figure 1Flow diagram of study patients and imaging findings.
Clinical characteristics of patients with primary hyperparathyroidism who underwent parathyroidectomy
| Characteristic | Total n=35 |
|---|---|
| Mean age, year (SD | 53 ± 13.48 |
| Female gender (%) | 22 (62.86) |
| Presentation (%) | |
| Asymptomatic | 3 (8.57) |
| Specific signs and symptoms | |
| Osteoporosis or osteopenia | 18 (51.43) |
| Nephrolithiasis and nephrocalcinosis | 17 (48.57) |
| Bone fracture | 4 (11.43) |
| Nonspecific signs and symptoms | |
| Constitutional symptoms | |
| Easy fatigability, lethargy or weakness | 12 (34.29) |
| Weight loss | 6 (17.14) |
| Gastrointestinal symptoms | 11 (31.43) |
| Nausea or vomiting | 2 (5.71) |
| Abdominal pain | 6 (17.14) |
| Constipation | 3 (8.57) |
| Anorexia | 1 (2.86) |
| Pancreatitis | 1 (2.86) |
| Peptic ulcer or gastroesophageal reflux disease | 4 (11.43) |
| Muscle or joint pains | 15 (42.86) |
| Psychiatric or behavioral changes | 7 (20) |
| Palpitations or chest pain | 6 (17.14) |
| Others | 10 (28.57) |
| Medical history | |
| Hypertension | 22 (62.86) |
| Thyroid disease | 27 (77.14) |
| Diabetes | 14 (40) |
| Chronic kidney disease | 12 (34.29) |
| Stage 1 | 1 (8.33) |
| Stage 2 | 2 (16.67) |
| Stage 3 | 8 (66.67) |
| Stage 4 | 1 (8.33) |
| Heart or coronary artery disese | 4 (11.43) |
| Lithium intake | 1 (2.86) |
| Neck radiation exposure | 0 |
| Thiazide use | 2 (5.71) |
| Others | 10 (28.57) |
| Family history | |
| Thyroid disease | 9 (25.71) |
| Parathyroid disease | 1 (2.86) |
SD, standard deviation
Preoperative laboratory profiles
| All subjects (n = 35) | CKD | Reference range | |
|---|---|---|---|
| Ionized calcium, mg/dL | 6.12 (5.45-8.44) | 6.56 (5.48-8.44) | 4.6-5.32 |
| iPTH | 202.6 (69.89-849.4) | 261.05 (118-849.4) | 15-65 |
| Phosphorus, mg/dL | 2.63 (1.95-3.5) | 2.59 (2.24-2.91) | 2.29-4.71 |
| Vitamin D, ng/mL | 25.8 (12.1-42.22) | 26.56 (12.99-42.22) | >30 |
| Serum creatinine, mg/dL | 1.06 (0.48-2.4) | 1.49 (1.17-2.4) | 0.55-1.02 |
| eGFR | 66 (21-120) | 44 (21-64.5) | >120 |
Median laboratory values. Ranges given in parentheses.
iPTH, intact parathyroid hormone
eGFR, estimated glomerular filtration rate, by CKD-EPI equation
CKD, chronic kidney disease
Operative and histopathologic profiles
| Characteristic | Mean or frequency |
|---|---|
| Estimated duration of signs and symptoms prior to surgery, year (range) | 2 (0.04-13) |
| Estimated time from diagnosis to surgery, month (range) | 4 (0.25-72) |
| Frequency of surgical indications (%) | |
| Osteoporosis/osteopenia | 18 (51.43) |
| Nephrolithiasis | 17 (48.57) |
| Muscle or joint pains | 15 (42.86) |
| Age <50 years | 14 (40) |
| Easy fatigability/lethargy | 12 (34.29) |
| Gastrointestinal symptoms | 11 (31.43) |
| eGFR | 9 (25.71) |
| Fracture | 4 (11.43) |
| Suggestive of cancer | 1 (2.86) |
| Surgery performed (%) | |
| Parathyroidectomy only | 15 (42.86) |
| Total thyroidectomy + parathyroidectomy | 9 (25.71) |
| Thyroid lobectomy + parathyroidectomy | 8 (22.86) |
| Subtotal thyroidectomy + parathyroidectomy | 3 (8.57) |
| Largest size of parathyroid lesion per subject (n=33) (%) | |
| ≤1 cm | 7 (21.21) |
| 1.1 to 2.0 cm | 15 (45.45) |
| 2.1 to 3.0 cm | 8 (24.24) |
| >3 cm | 3 (9.09) |
| Actual largest size of parathyroid lesion, cm (SD | 1.83 (0.92) |
| Type of suspected parathyroid lesions detected through imaging (n=42) (%) | |
| Non-pathologic | 6 (14.29) |
| Pathologic | 36 (85.7) |
| Adenoma | 31 (86.1) |
| Hyperplasia | 5 (13.9) |
eGFR, estimated glomerular filtration rate, by CKD-EPI equation
SD, standard deviation
Individual preoperative imaging results of each specimen (n=35)
| Non-pathological (n=6) | Adenoma (n=31) | Hyperplasia (n=5) | Total lesions (n=42) | |
|---|---|---|---|---|
| UTZ | ||||
| Positive | 0 | 18 (58.06) | 0 | 18 (42.86) |
| Negative | 3 (50) | 12 (38.71) | 4 (80) | 19 (45.24) |
| No imaging | 3 (50) | 1 (3.23) | 1 (20) | 5 (11.9) |
| MIBI | ||||
| Positive | 6 (100) | 25 (80.65) | 5 (100) | 36 (85.71) |
| Negative | 0 | 4 (12.9) | 0 | 4 (9.52) |
| No imaging | 0 | 2 (6.45) | 0 | 2 (4.76) |
UTZ, neck ultrasound
MIBI, 99mTc-sestamibi scan
Combined preoperative imaging results of each specimen (n=31)
| Non-pathological (n=6) | Adenoma (n=31) | Hyperplasia (n=5) | Total lesions (n=42) | |
|---|---|---|---|---|
| Positive on both (%) | 0 | 15 (53.57) | 0 | 15 (42.86) |
| Positive UTZ | 0 | 2 (7.14) | 0 | 2 (5.71) |
| Negative UTZ | 3 (100) | 9 (32.14) | 4 (100) | 16 (45.71) |
| Negative on both (%) | 0 | 2 (7.14) | 0 | 2 (5.71) |
UTZ, neck ultrasound
MIBI, 99mTc-sestamibi scan
Figure 2Preoperative imaging detection and localization rates of confirmed pathologic lesions in patients with both UTZ and MIBI.
Concordance in localization between imaging and surgical histopathology findings
| Agreement (%) | Expected agreement (%) | kappa | |
|---|---|---|---|
| UTZ | 54.05 | 26.52 | 0.375 |
| MIBI | 72.50 | 40.88 | 0.535 |
UTZ, neck ultrasound
MIBI, 99mTc-sestamibi scan
kappa statistic interpretation according to Landis and Koch: ≤0, none; 0-0.20, poor; 0.20-0.40, fair; 0.40-0.60, moderate; 0.60-0.80, substantial; 0.8-1, almost perfect; 1, perfect